ArticleUrolithiasis2025
Nonsteroidal anti-inflammatory drugs, blood metabolites, and kidney stones: a comprehensive Mendelian randomization study.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
It remains unclear for the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on kidney stones. This study aimed to investigate the causal relationship between NSAIDs medication usage and the risk of kidney stones, and further determine whether blood metabolites mediate this association. We conducted a two-sample Mendelian randomization (MR) analysis using genetic data from the FinnGen consortium to explore the causal impact of NSAIDs medication usage on kidney stone formation. Furthermore, a two-step MR analysis was performed to assess whether blood metabolites significantly mediate the effects of NSAIDs on kidney stone risk. Genetic variants associated with NSAIDs medication usage or blood metabolites were employed as instrumental variables. The inverse variance weighted (IVW) method serves as the primary analytical approach to assess the causal relationship. We found that NSAIDs usage was causally associated with an increased risk of kidney stones (OR: 1.70, 95% CI: 1.33-2.16, P < 0.001). Additionally, we revealed that the risk of kidney stones was causally affected by 67 blood metabolites, among which NSAIDs usage was causally associated with three metabolites, including β-hydroxyisovaleroylcarnitine level, Mannose level, and Deoxycholic acid 12-sulfate. Furthermore, mediation analysis revealed that β-hydroxyisovaleroylcarnitine partially mediated the effect of NSAIDs usage on kidney stones, accounting for approximately 5.6%. Our study suggests a potentially causal association between NSAIDs medication usage and an increased risk of kidney stones, with blood metabolites possibly mediating this effect. These insights underline the necessity of monitoring blood metabolite levels during NSAIDs therapy, especially in patients at risk for kidney stones. However, further studies are required to validate these findings.
Indexed as
Identifiers
40274636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.